2024

1. 4CMenB journey to the 10-year anniversary and beyond

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

2. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

   Journal of Infectious Diseases, Vol. 229, pp. S112-S119

3. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

4. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

5. COVID-19 InfoVaccines: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

6. Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein–Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational Study

   Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 9, pp. 2454-2467.e8

7. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

   Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

8. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

   The Lancet Infectious Diseases, Vol. 24, Núm. 8, pp. 817-828

9. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

   Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 78, Núm. 6, pp. 1732-1744

10. Erratum to «Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper» (Archivos de Bronconeumología (2024) 60(3) (161–170), (S0300289624000061), (10.1016/j.arbres.2024.01.004))

    Archivos de Bronconeumologia

11. GUANIN: an all-in-one GUi-driven analyzer for NanoString interactive normalization

    Bioinformatics, Vol. 40, Núm. 8

12. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

13. How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?

    Influenza and other Respiratory Viruses, Vol. 18, Núm. 6

14. Integration and validation of host transcript signatures, including a novel 3-transcript tuberculosis signature, to enable one-step multiclass diagnosis of childhood febrile disease

    Journal of Translational Medicine, Vol. 22, Núm. 1

15. Interferon gene expression declines over time post-COVID infection and in long COVID patients

    Infectious Diseases

16. Multi-tissue transcriptomics of a unique monozygotic discordant twin case of severe progressive osseous heteroplasia

    Genes and Diseases, Vol. 11, Núm. 3

17. Mycoplasma pneumoniae at the rise not only in China: rapid increase of Mycoplasma pneumoniae cases also in Spain

    Emerging Microbes and Infections

18. New Vaccines for Chronic Respiratory Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 9, pp. 565-575

19. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

20. Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases

    The Pediatric infectious disease journal, Vol. 43, Núm. 5, pp. 444-453